Last reviewed · How we verify
NCT03156231
Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease
Phase 4 trial testing ACETAZOLAMIDE oral capsule in Chronic Obstructive Pulmonary Disease (COPD) in 185 participants. Completed in 2 August 2018.
2 August 2018
Quick facts
| Lead sponsor | University of Zurich |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 185 |
| Start date | 24 May 2017 |
| Primary completion | 2 August 2018 |
| Estimated completion | 2 August 2018 |
| Sites | 1 location across Kyrgyzstan |
Drugs / interventions tested
- ACETAZOLAMIDE oral capsule — full drug profile →
- Placebo oral capsule
Conditions studied
- Chronic Obstructive Pulmonary Disease (COPD) — all drugs for Chronic Obstructive Pulmonary Disease (COPD) →
Sponsor
University of Zurich
Who can join
Adults 18 to 75, any sex, with Chronic Obstructive Pulmonary Disease (COPD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized, placebo controlled trial evaluating efficacy of acetazolamide in preventing altitude related adverse health effects (ARAHE) in lowlanders with chronic obstructive lung disease travelling from 760 m to 3200 m.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Acetazolamide to Prevent Adverse Altitude Effects in COPD and Healthy Adults.
Furian M, Mademilov M, Buergin A, Scheiwiller PM, et al · · 2022 · cited 30× · PMID 38296630 · DOI 10.1056/evidoa2100006 -
Effects of acetazolamide on exercise performance in patients with COPD going to high altitude: randomised controlled trial.
Kind RF, Furian M, Buergin A, Scheiwiller PM, et al · · 2025 · cited 3× · PMID 39834599 · DOI 10.1183/23120541.00767-2024 -
Nocturnal cerebral oxygenation in patients with COPD at altitude: data from a randomized clinical trial of acetazolamide.
Schmuziger YA, Mademilov M, Buergin A, Scheiwiller PM, et al · · 2025 · cited 1× · PMID 41025408 · DOI 10.5664/jcsm.11868 -
Electrocardiographic signs of cardiac ischemia at rest and during exercise in patients with COPD traveling to 3,100 m: data from a randomized trial of acetazolamide.
Christen M, Buergin A, Mademilov M, Mayer L, et al · · 2025 · PMID 39981351 · DOI 10.3389/fcvm.2025.1524201 -
Electrocardiographic signs of cardiac ischemia at rest and during exercise in patients with COPD travelling to 3100 m. Data from a randomized trial of acetazolamide
Christen M, Buergin A, Mademilov M, Mayer L, et al · · 2024 · DOI 10.1101/2024.11.12.24317157
Verify or expand the search:
- PubMed search for NCT03156231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ACETAZOLAMIDE oral capsule
Trials testing the same drug.
- NCT07517068 — The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude · EARLY_PHASE1 · active not recruiting
- NCT03540914 — Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. · Phase 4 · unknown
- NCT03537924 — Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude · Phase 4 · unknown
- NCT03539367 — Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude · Phase 4 · unknown
- NCT03540901 — Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude · Phase 4 · completed
Other recruiting trials for Chronic Obstructive Pulmonary Disease (COPD)
Currently open trials in the same condition.
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07355868 — Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy · EARLY_PHASE1 · recruiting
- NCT06892210 — Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) · Phase 4 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07519603 — Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program · NA · recruiting
Other University of Zurich trials
Trials by the same sponsor.
- NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
- NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
- NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03156231 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Zurich
- Last refreshed: 29 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03156231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing